XML 38 R25.htm IDEA: XBRL DOCUMENT
v3.24.3

REVENUES (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Revenue from Contract with Customer [Abstract] |
Summary of Total Revenues | The following table summarizes our Total revenues:
|  | Three Months Ended September 30, 2024 |  | Three Months Ended September 30, 2023
(in millions) |  | U.S. |  | Europe |  | Rest of World |  | Total |  | U.S. |  | Europe |  | Rest of World |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 2,826 |  |  | $ | 375 |  |  | $ | 272 |  |  | $ | 3,472 |  |  | $ | 2,504 |  |  | $ | 313 |  |  | $ | 268 |  |  | $ | 3,085 |
Descovy |  | 534 |  |  | 24 |  |  | 28 |  |  | 586 |  |  | 460 |  |  | 25 |  |  | 26 |  |  | 511 |
Genvoya |  | 384 |  |  | 44 |  |  | 21 |  |  | 449 |  |  | 433 |  |  | 47 |  |  | 23 |  |  | 503 |
Odefsey |  | 248 |  |  | 69 |  |  | 9 |  |  | 326 |  |  | 257 |  |  | 74 |  |  | 11 |  |  | 343 |
Symtuza - Revenue share(1) |  | 103 |  |  | 33 |  |  | 3 |  |  | 139 |  |  | 96 |  |  | 32 |  |  | 3 |  |  | 131 |
Other HIV(2) |  | 65 |  |  | 26 |  |  | 9 |  |  | 100 |  |  | 56 |  |  | 28 |  |  | 9 |  |  | 94 |
Total HIV |  | 4,161 |  |  | 570 |  |  | 342 |  |  | 5,073 |  |  | 3,807 |  |  | 519 |  |  | 341 |  |  | 4,667 |
Liver Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sofosbuvir/Velpatasvir(3) |  | 222 |  |  | 67 |  |  | 96 |  |  | 385 |  |  | 215 |  |  | 76 |  |  | 85 |  |  | 377 |
Vemlidy |  | 126 |  |  | 11 |  |  | 95 |  |  | 232 |  |  | 112 |  |  | 9 |  |  | 106 |  |  | 228 |
Other Liver Disease(4) |  | 45 |  |  | 54 |  |  | 17 |  |  | 116 |  |  | 49 |  |  | 33 |  |  | 20 |  |  | 102 |
Total Liver Disease |  | 393 |  |  | 132 |  |  | 207 |  |  | 733 |  |  | 376 |  |  | 119 |  |  | 211 |  |  | 706 |
Veklury |  | 393 |  |  | 81 |  |  | 219 |  |  | 692 |  |  | 258 |  |  | 65 |  |  | 313 |  |  | 636 |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 63 |  |  | 29 |  |  | 6 |  |  | 98 |  |  | 64 |  |  | 27 |  |  | 4 |  |  | 96 |
Yescarta |  | 145 |  |  | 182 |  |  | 60 |  |  | 387 |  |  | 197 |  |  | 154 |  |  | 40 |  |  | 391 |
Total Cell Therapy |  | 208 |  |  | 211 |  |  | 66 |  |  | 485 |  |  | 261 |  |  | 181 |  |  | 45 |  |  | 486 |
Trodelvy |  | 226 |  |  | 80 |  |  | 26 |  |  | 332 |  |  | 201 |  |  | 62 |  |  | 21 |  |  | 283 |
Total Oncology |  | 433 |  |  | 291 |  |  | 92 |  |  | 816 |  |  | 462 |  |  | 243 |  |  | 65 |  |  | 769 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 6 |  |  | 71 |  |  | 52 |  |  | 130 |  |  | 12 |  |  | 63 |  |  | 39 |  |  | 115 |
Other(5) |  | 47 |  |  | 8 |  |  | 16 |  |  | 71 |  |  | 69 |  |  | 9 |  |  | 23 |  |  | 101 |
Total Other |  | 53 |  |  | 80 |  |  | 68 |  |  | 201 |  |  | 82 |  |  | 72 |  |  | 62 |  |  | 216 |
Total product sales |  | 5,433 |  |  | 1,154 |  |  | 928 |  |  | 7,515 |  |  | 4,985 |  |  | 1,017 |  |  | 992 |  |  | 6,994 |
Royalty, contract and other revenues |  | 17 |  |  | 13 |  |  | 1 |  |  | 30 |  |  | 32 |  |  | 23 |  |  | 1 |  |  | 56 |
Total revenues |  | $ | 5,450 |  |  | $ | 1,167 |  |  | $ | 929 |  |  | $ | 7,545 |  |  | $ | 5,017 |  |  | $ | 1,040 |  |  | $ | 993 |  |  | $ | 7,051 |
|  | Nine Months Ended September 30, 2024 |  | Nine Months Ended September 30, 2023
(in millions) |  | U.S. |  | Europe |  | Rest of World |  | Total |  | U.S. |  | Europe |  | Rest of World |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 7,726 |  |  | $ | 1,110 |  |  | $ | 814 |  |  | $ | 9,649 |  |  | $ | 7,104 |  |  | $ | 920 |  |  | $ | 717 |  |  | $ | 8,741 |
Descovy |  | 1,339 |  |  | 75 |  |  | 82 |  |  | 1,496 |  |  | 1,314 |  |  | 75 |  |  | 86 |  |  | 1,475 |
Genvoya |  | 1,088 |  |  | 138 |  |  | 66 |  |  | 1,292 |  |  | 1,305 |  |  | 157 |  |  | 81 |  |  | 1,544 |
Odefsey |  | 705 |  |  | 217 |  |  | 30 |  |  | 952 |  |  | 754 |  |  | 223 |  |  | 33 |  |  | 1,011 |
Symtuza - Revenue share(1) |  | 338 |  |  | 101 |  |  | 9 |  |  | 448 |  |  | 278 |  |  | 101 |  |  | 10 |  |  | 390 |
Other HIV(2) |  | 190 |  |  | 96 |  |  | 36 |  |  | 322 |  |  | 192 |  |  | 91 |  |  | 38 |  |  | 321 |
Total HIV |  | 11,386 |  |  | 1,737 |  |  | 1,038 |  |  | 14,160 |  |  | 10,949 |  |  | 1,568 |  |  | 965 |  |  | 13,482 |
Liver Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sofosbuvir/Velpatasvir(3) |  | 737 |  |  | 230 |  |  | 299 |  |  | 1,266 |  |  | 643 |  |  | 250 |  |  | 266 |  |  | 1,159 |
Vemlidy |  | 338 |  |  | 33 |  |  | 328 |  |  | 699 |  |  | 295 |  |  | 28 |  |  | 322 |  |  | 645 |
Other Liver Disease(4) |  | 134 |  |  | 148 |  |  | 55 |  |  | 337 |  |  | 113 |  |  | 112 |  |  | 64 |  |  | 289 |
Total Liver Disease |  | 1,210 |  |  | 411 |  |  | 682 |  |  | 2,302 |  |  | 1,051 |  |  | 390 |  |  | 652 |  |  | 2,093 |
Veklury |  | 784 |  |  | 204 |  |  | 473 |  |  | 1,461 |  |  | 607 |  |  | 227 |  |  | 630 |  |  | 1,465 |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 181 |  |  | 102 |  |  | 22 |  |  | 305 |  |  | 179 |  |  | 83 |  |  | 11 |  |  | 272 |
Yescarta |  | 502 |  |  | 509 |  |  | 170 |  |  | 1,181 |  |  | 624 |  |  | 408 |  |  | 99 |  |  | 1,130 |
Total Cell Therapy |  | 683 |  |  | 611 |  |  | 192 |  |  | 1,485 |  |  | 802 |  |  | 491 |  |  | 109 |  |  | 1,402 |
Trodelvy |  | 655 |  |  | 217 |  |  | 88 |  |  | 960 |  |  | 551 |  |  | 169 |  |  | 44 |  |  | 764 |
Total Oncology |  | 1,338 |  |  | 828 |  |  | 280 |  |  | 2,446 |  |  | 1,354 |  |  | 660 |  |  | 153 |  |  | 2,167 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 37 |  |  | 210 |  |  | 176 |  |  | 424 |  |  | 39 |  |  | 192 |  |  | 150 |  |  | 381 |
Other(5) |  | 203 |  |  | 26 |  |  | 52 |  |  | 281 |  |  | 197 |  |  | 31 |  |  | 49 |  |  | 277 |
Total Other |  | 241 |  |  | 236 |  |  | 228 |  |  | 705 |  |  | 236 |  |  | 224 |  |  | 199 |  |  | 658 |
Total product sales |  | 14,958 |  |  | 3,416 |  |  | 2,700 |  |  | 21,074 |  |  | 14,196 |  |  | 3,069 |  |  | 2,599 |  |  | 19,864 |
Royalty, contract and other revenues |  | 66 |  |  | 43 |  |  | 2 |  |  | 111 |  |  | 57 |  |  | 77 |  |  | 4 |  |  | 138 |
Total revenues |  | $ | 15,024 |  |  | $ | 3,459 |  |  | $ | 2,703 |  |  | $ | 21,185 |  |  | $ | 14,253 |  |  | $ | 3,146 |  |  | $ | 2,603 |  |  | $ | 20,002 |
_______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). (2) Includes Atripla, Complera/Eviplera, Emtriva, Sunlenca, Stribild, Truvada and Tybost. (3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”). (4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi, Sovaldi, Viread and Vosevi. (5) Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig.
Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods | The following table summarizes revenues recognized from performance obligations satisfied in prior years:
| Three Months Ended |  | Nine Months Ended
| September 30, |  | September 30,
(in millions) | 2024 |  | 2023 |  | 2024 |  | 2023
Revenue share with Janssen and royalties for licenses of intellectual property | $ | 173 |  |  | $ | 166 |  |  | $ | 545 |  |  | $ | 517 |
Changes in estimates | $ | 146 |  |  | $ | 111 |  |  | $ | 388 |  |  | $ | 347 |
Summary of Contract Balances | The following table summarizes our contract balances:
(in millions) |  | September 30, 2024 |  | December 31, 2023
Contract assets |  | $ | 184 |  |  | $ | 117 |
Contract liabilities |  | $ | 68 |  |  | $ | 109 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration